Caplin Point Laboratories Toekomstige groei

Future criteriumcontroles 2/6

Caplin Point Laboratories zal naar verwachting groeien in winst en omzet met respectievelijk 13.6% en 13.2% per jaar. De winst per aandeel zal naar verwachting groeien met 13.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 18.6% zijn.

Belangrijke informatie

13.6%

Groei van de winst

13.6%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	17.5%
Inkomstengroei	13.2%
Toekomstig rendement op eigen vermogen	18.6%
Dekking van analisten	Low
Laatst bijgewerkt	11 Nov 2024

Recente toekomstige groei-updates

₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results

Nov 10

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Aug 11

Recent updates

Investor Optimism Abounds Caplin Point Laboratories Limited (NSE:CAPLIPOINT) But Growth Is Lacking

Dec 01

₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results

Nov 10

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Oct 31

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50

Sep 12

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Aug 11

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50

Aug 10

Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Earnings

Jul 12

Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues

May 24

Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?

May 04

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement

Mar 07

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Oct 24

Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise

Sep 15

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50

Aug 11

We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise

Sep 23

Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year

Sep 11

Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?

Jul 22

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00

May 15

A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)

Jan 21

Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?

Oct 20

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹1.50

Sep 17

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹1.50

Sep 03

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Intrinsic Value Is Potentially 28% Above Its Share Price

Aug 27

Is Caplin Point Laboratories (NSE:CAPLIPOINT) A Risky Investment?

Jun 12

Winst- en omzetgroeiprognoses

NSEI:CAPLIPOINT - Toekomstschattingen van analisten en financiële gegevens uit het verleden (INR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2027	25,604	7,061	5,040	5,119	1
3/31/2026	22,369	5,806	4,138	5,220	3
3/31/2025	19,665	5,069	3,174	4,027	3
9/30/2024	18,328	4,936	2,310	3,748	N/A
6/30/2024	17,577	4,776	N/A	N/A	N/A
3/31/2024	16,961	4,571	1,726	3,184	N/A
12/31/2023	16,318	4,376	N/A	N/A	N/A
9/30/2023	15,683	4,179	399	2,593	N/A
6/30/2023	15,157	3,947	N/A	N/A	N/A
3/31/2023	14,683	3,763	779	2,714	N/A
12/31/2022	14,182	3,532	N/A	N/A	N/A
9/30/2022	13,724	3,307	2,305	3,467	N/A
6/30/2022	13,153	3,140	N/A	N/A	N/A
3/31/2022	12,710	2,998	2,456	3,367	N/A
12/31/2021	12,099	2,872	N/A	N/A	N/A
9/30/2021	11,581	2,767	1,288	2,044	N/A
6/30/2021	11,217	2,586	N/A	N/A	N/A
3/31/2021	10,624	2,423	1,953	2,686	N/A
12/31/2020	9,986	2,248	N/A	N/A	N/A
9/30/2020	9,524	2,189	1,650	1,877	N/A
6/30/2020	9,107	2,193	N/A	N/A	N/A
3/31/2020	8,640	2,150	-321	447	N/A
12/31/2019	8,356	2,159	N/A	N/A	N/A
9/30/2019	7,664	2,032	-331	830	N/A
6/30/2019	6,948	1,894	N/A	N/A	N/A
3/31/2019	6,490	1,766	182	834	N/A
12/31/2018	6,048	1,621	N/A	N/A	N/A
9/30/2018	5,874	1,538	N/A	N/A	N/A
6/30/2018	5,628	1,459	N/A	N/A	N/A
3/31/2018	5,399	1,448	N/A	665	N/A
12/31/2017	5,145	1,430	N/A	N/A	N/A
9/30/2017	4,757	1,297	N/A	N/A	N/A
6/30/2017	4,401	1,165	N/A	N/A	N/A
3/31/2017	4,016	956	N/A	676	N/A
12/31/2016	3,655	783	N/A	N/A	N/A
9/30/2016	3,420	703	N/A	N/A	N/A
6/30/2016	3,238	619	N/A	N/A	N/A
3/31/2016	3,088	584	N/A	565	N/A
12/31/2015	2,906	535	N/A	N/A	N/A
9/30/2015	2,722	465	N/A	N/A	N/A
6/30/2015	2,518	410	N/A	499	N/A
3/31/2015	2,296	353	N/A	N/A	N/A
12/31/2014	2,074	318	N/A	N/A	N/A
9/30/2014	1,893	305	N/A	N/A	N/A
6/30/2014	1,731	258	N/A	598	N/A
3/31/2014	1,643	204	N/A	N/A	N/A
12/31/2013	1,517	167	N/A	N/A	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei CAPLIPOINT ( 13.6% per jaar) ligt boven de spaarquote ( 6.7% ).

Winst versus markt: De winst van CAPLIPOINT ( 13.6% per jaar) zal naar verwachting langzamer groeien dan de markt Indian ( 18.1% per jaar).

Hoge groeiwinsten: De winst van CAPLIPOINT zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van CAPLIPOINT ( 13.2% per jaar) zal naar verwachting sneller groeien dan de markt Indian ( 10.5% per jaar).

Hoge groei-inkomsten: De omzet van CAPLIPOINT ( 13.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen CAPLIPOINT zal naar verwachting over 3 jaar laag zijn ( 18.6 %).

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2024/12/22 10:52
Aandelenkoers aan het einde van de dag	2024/12/20 00:00
Inkomsten	2024/09/30
Jaarlijkse inkomsten	2024/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

Caplin Point Laboratories Limited wordt gevolgd door 3 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Rohit Bhat	Batlivala & Karani Securities India Pvt. Ltd.
Kameswari V. S. Chavali	FirstCall Research
Siddhant Khandekar	ICICIdirect.com

Caplin Point Laboratories Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results

Price target increased by 14% to ₹2,142

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Price target increased by 17% to ₹1,717

Price target increased by 8.0% to ₹1,076

Price target increased to ₹948

Recent updates

Investor Optimism Abounds Caplin Point Laboratories Limited (NSE:CAPLIPOINT) But Growth Is Lacking

₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results

Caplin Point Laboratories Limited Announces Cessation of D Sathyanarayanan as an Independent Director

Second quarter 2025 earnings released: EPS: ₹17.22 (vs ₹15.13 in 2Q 2024)

Caplin Point Laboratories Limited to Report Q2, 2025 Results on Nov 07, 2024

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Price target increased by 14% to ₹2,142

Upcoming dividend of ₹2.50 per share

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 19%

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50

Price target increased by 17% to ₹1,717

Dividend of ₹2.50 announced

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Caplin Point Laboratories Limited, Annual General Meeting, Sep 30, 2024

Caplin Point Laboratories Limited to Report Q1, 2025 Results on Aug 07, 2024

Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Earnings

Caplin Point Laboratories Limited Appoints Thiagaraja Manikandan as Chief Transformation & Digital Officer

Investor sentiment improves as stock rises 18%

Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues

Full year 2024 earnings: Revenues in line with analyst expectations

Caplin Point Laboratories Limited Declares an Interim Dividend for the Financial Year Ended March 31, 2024

Caplin Point Laboratories Limited to Report Fiscal Year 2024 Results on May 16, 2024

Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement

Third quarter 2024 earnings released: EPS: ₹15.44 (vs ₹12.86 in 3Q 2023)

Caplin Point Laboratories Limited to Report Q3, 2024 Results on Feb 09, 2024

Investor sentiment improves as stock rises 16%

Price target increased by 8.0% to ₹1,076

Second quarter 2024 earnings released: EPS: ₹15.13 (vs ₹12.09 in 2Q 2023)

Caplin Point Laboratories Limited to Report Q2, 2024 Results on Nov 09, 2023

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023

Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise

Upcoming dividend of ₹2.50 per share at 0.5% yield

Caplin Point Laboratories Limited, Annual General Meeting, Sep 21, 2023

Investor sentiment improves as stock rises 15%

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023

First quarter 2024 earnings released: EPS: ₹13.62 (vs ₹11.21 in 1Q 2023)

Caplin Point Laboratories Limited to Report Q1, 2024 Results on Aug 07, 2023

Caplin Steriles Limited Gets United States Food and Drug Administration Approval for Cisatracurium Besylate Injection USP

Upcoming dividend of ₹2.00 per share at 0.3% yield

Full year 2023 earnings: EPS exceeds analyst expectations

Caplin Point Laboratories Limited to Report Q4, 2023 Results on May 24, 2023

Now 20% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: ₹12.86 (vs ₹9.90 in 3Q 2022)

Caplin Point Laboratories Limited to Report Q3, 2023 Results on Feb 11, 2023

Price target increased to ₹948

Caplin Point Laboratories Limited (BSE:524742) acquired API plant in Vizag from Metrochem API Private Limited.

Second quarter 2023 earnings released: EPS: ₹12.09 (vs ₹9.91 in 2Q 2022)

Caplin Point Laboratories Limited to Report Q2, 2023 Results on Nov 12, 2022

Caplin Point Laboratories Limited Approves Final Dividend for the Financial Year Ended March 31, 2022

Caplin Point Laboratories Limited Announces Change in Directorate

We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise

Upcoming dividend of ₹2.00 per share

Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year

Caplin Point Laboratories Limited, Annual General Meeting, Sep 29, 2022

Caplin Point Laboratories Limited, Annual General Meeting, Sep 29, 2022

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

First quarter 2023 earnings released: EPS: ₹11.21 (vs ₹9.37 in 1Q 2022)

Caplin Point Laboratories Limited to Report Q1, 2023 Results on Aug 05, 2022

Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?

Caplin Point Laboratories Limited Announces Resignation of D P Mishra as Non-Executive, Non-Independent Director

Investor sentiment improved over the past week

Upcoming dividend of ₹2.00 per share